ClinicalTrials.gg
Active, not recruitingNCT04954859B-SureUpdated Nov 5, 2026

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

A Phase 2 interventional study of Bepirovirsen and Placebo in Hepatitis B, sponsored by GlaxoSmithKline. Active, not recruiting at 161 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Updated Nov 5, 2026Enrollment updated5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
366
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.

Enrollment
4th of 16
366 · median 103
Started
2021
with 2 others
Phase 2
7 of 16
1 open now
Registered
6th of 16
by date
Lead sponsor
15 of 16
GlaxoSmithKline

Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 6th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bepirovirsen

bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bepirovirsen in Hepatitis B, or all of them as a file.
02

Study summary

This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear [209668: NCT04449029], B-Together [209348: NCT04676724], B-Fine [212602: NCT04544956], B-Well 1 [202009: NCT05630807], B-Well 2 [219288: NCT05630820], and TH HBV ASO-001 [217023: NCT05276297]). Participants will be categorized as Not-on-NA, NA-cessated, or On-NA based on their nucleos(t)ide analogue (NA) status in the parent study. No further treatment with bepirovirsen will be administered in this study.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Bepirovirsen
  • B-Sure
  • Nucleos(t)ide
  • Durability
  • HBsAg
  • Functional cure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who enter the study on stable NA are willing and able to cease their NA treatment in accordance with the NA cessation schedule.
  • Capable of giving .

For participants rolling over from 209668 (B-Clear), 209348 (B-Together), and 212602 (B-Fine):

  • Participants who have previously received at least one dose of bepirovirsen AND

    1. Achieved the PSPO in the parent study and who maintained a response until the End of Study (EoS) visit in their parent study (defined as complete responders to bepirovirsen from the parent study) OR
    2. Demonstrated virus surface antigen (HBsAg) reduction greater than or equal to (≥) 1.0 log10 international units per milliliter (IU/mL) from parent study Baseline with HBsAg levels less than (\<) 100 IU/mL and HBV deoxyribonucleic acid (DNA) \< lower limit of quantification (LLOQ) for 24 weeks after the actual end of treatment regimen, in the absence of rescue medication and maintained until their EoS visit in the parent study.

For participants rolling over from 202009 (B-Well1) and 219288 (B-Well 2):

  • Participants who have previously received at least 1 dose of bepirovirsen (or matching placebo where appropriate) AND

    1. NA cessated at Week 48 in parent study and achieved at least HBsAg \<1 IU/ml and HBV DNA \<LLOQ at the EOS visit (Week 96) in the parent study OR
    2. Achieved NA cessation criteria at Week 48 in parent study but have not stopped NA treatment, and are maintaining at least HBsAg \<1 IU/ml and HBV DNA \<LLOQ at EOS visit (Week 72) of parent study OR
    3. Did not achieve NA cessation criteria in parent study but achieved at least HBsAg \<1 IU/ml and HBV DNA \<LLOQ at EOS visit (Week 72) of parent study.

For participants rolling over from 217023 (TH HBV ASO-001):

  • Participants who have previously received at least 1 dose of bepirovirsen AND

    1. Achieved HBsAg \<1 IU/ml and HBV DNA \<LLOQ in parent study at Week 66 (ASO12 arm) or Week 78 (ASO 24 arm) and are maintaining HBsAg \< 1 IU/ml and HBV DNA \<LLOQ, at the EOS study visit [Week 133 ASO12 arm), or Week 145 (ASO24 arm)] in parent study OR
    2. Did not achieve HBsAg \<1 IU/ml and HBV DNA \<LLOQ in parent study at Week 66 (ASO12 arm) or Week 78 (ASO24 arm) but have achieved HBsAg \< 1 IU/ml and HBV DNA \< LLOQ by the EOS visit (Week 133 (ASO12 arm) or Week 145 (ASO24 arm)) in the parent study.

Exclusion criteria

Exclusion Criteria:

  • Participants who have/or are currently participating in another non-GSK interventional clinical study exploring treatment since completing their treatment with bepirovirsen.
  • Any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Not-on-NA participants

    Participants rolling over from study 209668 who have not received nucleos(t)ide analogue (NA) therapy during the parent study and remain off NAs will be included in this arm. Participants will be followed up for 33 months. Participants maintaining either functional cure (FC) or a partial response off NA treatment at Month 33 will be eligible to be followed up for an additional 2 years. No study treatment will be administered in this study.

    Drug: Bepirovirsen · Drug: Placebo

  • Experimental
    On-NA participants

    Participants rolling over from studies 209668, 209348, 212602, 202009, 219288, and 217023 who entered the parent study on stable NA therapy and remained on NA therapy for the duration of the treatment and follow-up periods in the parent study will be included in this arm. NA cessation will occur at 3 months in 206882 for eligible and willing participants. Participants will be followed up for 33 months. Participants rolling over from studies 209668 and 209348 who stopped NA treatment and are maintaining either FC or a partial response at Month 33, and remaining off NA treatment, will be eligible to be followed up for an additional 2 years. No study treatment will be administered in this study.

    Drug: Bepirovirsen · Drug: Placebo

  • Experimental
    NA-cessated participants

    Participants rolling over from studies 202009 and 219288 who have stopped NA treatment during the parent study will be included in this arm. Participants will be followed up for 33 months. No study treatment will be administered in this study.

    Drug: Bepirovirsen · Drug: Placebo

Interventions

  • No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.

  • DrugPlacebo

    No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.

06

What researchers measure

Primary outcomes

  1. Percentage of Not-on-NA participants without loss of parent study primary outcome (PSPO)

    NA indicates nucleos(t)ide analogue (NA).

    Time frame: From primary endpoint assessment in the parent study up to Month 57

  2. Percentage of On-NA participants rolling over from studies 209668 and 209348 without loss of functional cure (FC) after NA-cessation in study 206882

    Time frame: From Month 3 up to Month 57

  3. Percentage of On-NA participants rolling over from study 217023 without loss of FC after NA-cessation in study 206882

    Time frame: From Month 3 up to Month 33

  4. Percentage of NA-cessated participants rolling over from studies 202009 and 219288 without loss of FC after NA-cessation in the parent study

    Time frame: From primary endpoint assessment in the parent study up to Month 33

Secondary outcomes

  1. Percentage of On-NA and NA-cessated participants with PSPO in the parent study who have hepatitis B surface antigen (HBsAg) reversion or use of any rescue medication after NA cessation (in either parent study or study 206682)

    Time frame: Up to Month 57

  2. Percentage of On-NA and NA-cessated participants with PSPO in the parent study who have virologic relapse or use of any rescue medication after NA cessation (in either parent study or study 206682)

    Time frame: Up to Month 57

  3. Percentage of On-NA and NA-cessated participants with PSPO in the parent study who have clinical relapse or use of any rescue medication after NA cessation (in either parent study or study 206682)

    Time frame: Up to Month 57

  4. Percentage of On-NA and NA-cessated participants with PSPO in the parent study who receive NA retreatment after NA cessation (in either parent study or study 206682)

    Time frame: Up to Month 57

  5. Percentage of On-NA participants with PSPO in the parent study, who continue NA treatment in study 206882, and have no loss of treatment response

    Time frame: From primary endpoint assessment in the parent study up to Month 33

  6. Percentage of Not-on-NA participants with a partial response in the parent study and a delayed FC in study 206882 in absence of rescue medication after end of treatment in the parent study

    Time frame: Up to Month 57

  7. Time to loss of FC from time of achieving delayed FC in Not-on-NA participants with a partial response in the parent study and a delayed FC in study 206882

    Time frame: From date of achieving delayed FC up to Month 57

  8. Percentage of On-NA participants with a partial response in the parent study, who discontinue NA treatment in study 206882, and have a delayed FC in 206882 in absence of rescue medication after end of treatment in the parent study

    Time frame: Up to Month 57

  9. Time to loss of FC in On-NA participants who achieve a partial response in the parent study, discontinue NA treatment in study 206882 and achieve delayed FC in 206882

    Time frame: From date of achieving delayed FC up to Month 57

  10. Percentage of On-NA participants with a partial response in the parent study, who do not discontinue NA treatment in study 206882, and have a delayed treatment response in 206882 in absence of rescue medication after end of treatment in the parent study

    Time frame: Up to Month 33

  11. Time to loss of treatment response in On-NA participants who achieve a partial response in the parent study, do not discontinue NA treatment in study 206882 and have a delayed treatment response in 206882

    Time frame: From date of achieving delayed treatment response up to Month 33

  12. Percentage of On-NA participants with a partial response in the parent study, who discontinue NA treatment in study 206882, and have HBsAg loss in the absence of any rescue medication after NA cessation in 206882

    Time frame: From Month 3 to Month 57

  13. Percentage of On-NA participants with a partial response in the parent study, who discontinue NA treatment in study 206882, and have virologic relapse or use of any rescue medication after NA cessation in 206882

    Time frame: From Month 3 up to Month 57

  14. Percentage of On-NA participants with a partial response in the parent study, who discontinue NA treatment in study 206882, and have clinical relapse or use of any rescue medication after NA cessation in 206882

    Time frame: From Month 3 up to Month 57

  15. Percentage of On-NA participants with a partial response in the parent study, who discontinue NA treatment in study 206882 and have use of any rescue medication after NA cessation in 206882

    Time frame: From Month 3 up to Month 57

  16. Percentage of participants with anti-HBs (antibody to HBsAg)

    Time frame: Up to 57 months

  17. Percentage of participants with anti-HBe (antibody to hepatitis B e-antigen [HBeAg])

    Time frame: Up to 57 months

  18. Absolute values for HBsAg, hepatitis B virus (HBV) deoxyribonucleic acid (DNA), HBeAg (logarithm to the base 10 [log10] international units per milliliter [IU/mL])

    Time frame: Up to 57 months

  19. Change from Baseline for HBsAg, HBV DNA, HBeAg (log10 IU/mL)

    Time frame: Baseline (End of Study visit in the parent study) and up to 57 months

  20. Absolute values for hepatitis B core-related antigen (HBcrAg) (kiloUnits per milliliter [kU/mL])

    Time frame: Up to 57 months

  21. Change from Baseline for HBcrAg (kU/mL)

    Time frame: Baseline (End of Study visit in the parent study) and up to 57 months

  22. Absolute values for HBV ribonucleic acid (RNA) (log10 IU/ml)

    Time frame: Up to 57 months

  23. Change from Baseline for HBV RNA (log10 IU/ml)

    Time frame: Baseline (End of Study visit in the parent study) and up to 57 months

  24. Percentage of participants with mutations

    Time frame: Up to 57 months

07

Study locations

161 sites
  • GSK Investigational Site
    Sacramento, California 95817-1348, United States
  • GSK Investigational Site
    San Jose, California 95128, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    La Plata, Buenos Aires B1902AWL, Argentina
  • GSK Investigational Site
    Buenos Aires, C1181ACH, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • GSK Investigational Site
    Rosario, 2000, Argentina
  • GSK Investigational Site
    Santa Fe, 3000, Argentina
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
  • GSK Investigational Site
    Aracaju, Sergipe 49055-000, Brazil
  • GSK Investigational Site
    Campinas, 13060-803, Brazil
  • GSK Investigational Site
    Curitiba, 30140-073, Brazil
  • GSK Investigational Site
    Manaus, 69040000, Brazil
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
  • GSK Investigational Site
    Vila Mariana, 04121-000, Brazil
  • GSK Investigational Site
    Plovdiv, 4000, Bulgaria
  • GSK Investigational Site
    Sliven, 8800, Bulgaria
  • GSK Investigational Site
    Sofia, 1431, Bulgaria
  • GSK Investigational Site
    Sofia, 1463, Bulgaria
  • GSK Investigational Site
    Sofia, 1606, Bulgaria
  • GSK Investigational Site
    Varna, 9010, Bulgaria
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8R 6R3, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 0A9, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4G2, Canada
  • GSK Investigational Site
    Beijing, 100015, China
  • GSK Investigational Site
    Beijing, 100039, China
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Chengdu, 610072, China
  • GSK Investigational Site
    Chongqing, 400042, China
  • GSK Investigational Site
    Fuzhou, 350028, China
  • GSK Investigational Site
    Guangzhou, 510000, China
  • GSK Investigational Site
    Guangzhou, 510440, China
  • GSK Investigational Site
    Guangzhou, 510630, China
  • GSK Investigational Site
    Hangzhou, 310014, China
  • GSK Investigational Site
    Hangzhou, 310022, China
  • GSK Investigational Site
    Kunming, 650021, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 201508, China
  • GSK Investigational Site
    Shenzhen, 518112, China
  • GSK Investigational Site
    Tianjin, 300000, China
  • GSK Investigational Site
    Ürümqi, 830054, China
  • GSK Investigational Site
    Wuhan, 430030, China
  • GSK Investigational Site
    Xi'an, 710061, China
  • GSK Investigational Site
    Xiamen, 361015, China
  • GSK Investigational Site
    Zhenjiang, China
  • GSK Investigational Site
    Zunyi, 563114, China
  • GSK Investigational Site
    Clichy, 92110, France
  • GSK Investigational Site
    Lyon, 69317, France
  • GSK Investigational Site
    Paris, France
  • GSK Investigational Site
    Pessac, 33604, France
  • GSK Investigational Site
    Rennes, 35000, France
  • GSK Investigational Site
    Strasbourg, 67200, France
  • GSK Investigational Site
    Frankfurt am Main, Hesse 60329, Germany
  • GSK Investigational Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Athens, Attica 115 27, Greece
  • GSK Investigational Site
    Athens, 10676, Greece
  • GSK Investigational Site
    Heraklion, 711 10, Greece
  • GSK Investigational Site
    Kowloon, Hong Kong
  • GSK Investigational Site
    Pokfulam, Hong Kong
  • GSK Investigational Site
    Budapest, 1097, Hungary
  • GSK Investigational Site
    Belagavi, 590010, India
  • GSK Investigational Site
    Coimbatore, 641005, India
  • GSK Investigational Site
    Hyderabad, India
  • GSK Investigational Site
    Kanchan Bagh Hyderabad, 40000, India
  • GSK Investigational Site
    Mumbai, 400008, India
  • GSK Investigational Site
    Mumbai, 400012, India
  • GSK Investigational Site
    Mumbai, 400022, India
  • GSK Investigational Site
    New Delhi, 110070, India
  • GSK Investigational Site
    Pune, 411001, India
  • GSK Investigational Site
    Surat, 395002, India
  • GSK Investigational Site
    Bergamo, 24127, Italy
  • GSK Investigational Site
    Milan, 20122, Italy
  • GSK Investigational Site
    Milan, 20157, Italy
  • GSK Investigational Site
    Modena, 40126, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Palermo, 90127, Italy
  • GSK Investigational Site
    Pisa, 56124, Italy
  • GSK Investigational Site
    Gifu, 500-8717, Japan
  • GSK Investigational Site
    Gifu, 503-8502, Japan
  • GSK Investigational Site
    Hiroshima, 730-8619, Japan
  • GSK Investigational Site
    Hiroshima, 734-8551, Japan
  • GSK Investigational Site
    Hokkaido, 006-0811, Japan
  • GSK Investigational Site
    Ishikawa, 920-8650, Japan
  • GSK Investigational Site
    Kagawa, 760-8557, Japan
  • GSK Investigational Site
    Kumamoto, 860-8556, Japan
  • GSK Investigational Site
    Kumamoto, 862-8655, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Niigata, 950-1104, Japan
  • GSK Investigational Site
    Osaka, 565-0871, Japan
  • GSK Investigational Site
    Tokyo, 113-8519, Japan

Showing the first 100 of 161 sites across 29 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jan 2029, 85 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Hepatitis B, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's planned 85 months is above that.

Counting every sponsor, half of 50 studies reached it within 30 months; a quarter within 19 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2021
First posted
Jul 8, 2021
StartActual
Dec 14, 2021
Primary completionEst.
Jan 24, 2029
CompletionEst.
Jan 24, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 7 sites removed
Show 5 added (1 Germany, 1 Greece, 1 South Africa, 1 Spain, 1 United Kingdom)
  • GSK Investigational Site · Frankfurt am Main, Germany
  • GSK Investigational Site · Athens, Greece
  • GSK Investigational Site · Durban, South Africa
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Cottingham, United Kingdom
Show 7 removed
  • GSK Investigational Site · Liuzhou, China
  • GSK Investigational Site · Berlin, Germany
  • GSK Investigational Site · Frankfurt am Main, Germany
  • GSK Investigational Site · Athens, Greece
  • GSK Investigational Site · Durban, South Africa
  • GSK Investigational Site · HebrOn, Spain
  • GSK Investigational Site · Cottingham, United Kingdom
Nov 5, 2026
Enrollment
360 (estimated)→366 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    5 sites added, 7 sites removed
    Show 5 added (1 Germany, 1 Greece, 1 South Africa, 1 Spain, 1 United Kingdom)
    • GSK Investigational Site · Frankfurt am Main, Germany
    • GSK Investigational Site · Athens, Greece
    • GSK Investigational Site · Durban, South Africa
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Cottingham, United Kingdom
    Show 7 removed
    • GSK Investigational Site · Liuzhou, China
    • GSK Investigational Site · Berlin, Germany
    • GSK Investigational Site · Frankfurt am Main, Germany
    • GSK Investigational Site · Athens, Greece
    • GSK Investigational Site · Durban, South Africa
    • GSK Investigational Site · HebrOn, Spain
    • GSK Investigational Site · Cottingham, United Kingdom
    Enrollment 360 (estimated)→366 (actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04954859
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 8, 2021
Start date
Dec 14, 2021
Primary completion
Jan 24, 2029 (estimated)
Completion
Jan 24, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion